Subscribe Now

Thursday, August 30, 2018

Revolutionary blood test to detect early stage cancer

A revolutionary new blood test could significantly advance our ability for detecting cancer in its early stages. CancerSEEK, developed in John Hopkins University, could improve detection methods and consequently reduce mortality rates.

Cancer is often a treatable condition. However, in
many cases, it does not display symptoms for many years. As a result, a number of cancer cases are not detected until the later stages of the disease when it is not easy to treat, if it can be treated at all.

A large amount of cancer research is dedicated to treatments that do not seek to cure the condition but
to prolong the lives of those with terminal cancer.

These treatments are often only marginally beneficial,
sometimes prolonging the life of the individual only a few weeks. At most the effect of these medications is commonly gauged in months, rather than years.

Newer treatments can enter a six figure price range whilst only showing slight increases in survival time compared to older, cheaper medicines. An editorial in the British Medical Journal (BMJ) criticises this
practise as ethically questionable. Many individuals with terminal cancer will pay whatever it takes for those
few extra weeks.

The number of deaths due to cancer is declining. In the United States figures indicate a 25 percent fall between 1991 and 2014. This reduction in mortality rate was primarily attributed to advancements in early detection methods. In many cases tumours may be
removed entirely by surgery if detected early enough.

If the cancer has not spread the chance of remission is
relatively low, and can be reduced further through
therapies such as radiotherapy, chemotherapy and immunotherapy.

Cance rSEEK, a revolutionary
blood test CancerSEEK is, conceptually, a standard blood test capable of detecting sixteen genes and eight proteins
associated with tumour cells. Cancerous cells secrete
traces of these proteins into the bloodstream, allowing
for detection and therefore diagnosis. If a person
tests positive for one of these genes or proteins, follow up tests can then establish if the person has cancer.

The CancerSEEK test has been trialled in the detection
of eight different cancer types. Early results suggest
it can detect cancers originating in the ovary, liver,
stomach, pancreas, oesophagus, colon, lung and breast. This is a broad range of cancers with which to begin trials, covering many of the most common forms of

Initial trials were performed on 1,005 patients with non-metastatic, clinically detected and confirmed cancers. Results were promising, showing an average detection rate of seventy percent for the eight cancer types. The detection sensitivity ranged from 69
percent to 98 percent for the five cancer types (ovary, liver, stomach, pancreas, and esophagus) for which there are no screening tests available for
average-risk individuals.
The absent 30 percent of subjects who were not detected could likely be explained by the presence of other cancer causing genes. While the blood test currently encapsulates sixteen genes, there are
numerous others that can cause cancer that will not be
detected by the blood test. However, for an initial
trial, a seventy percent detection rate is fairly successful.

Success rates varied considerably, however, between
cancer types. Only 33% of breast cancer cases were
detected but the test had an accuracy rate of 98%
when detecting ovarian cancer. Some experts have stated that the test must first be improved in order to be successful as a broad spectrum cancer detection method. This would likely involve the inclusion of more genes commonly linked to tumour growth.

Currently the test is undergoing trials in a general
population group of 10,000 individuals in order to
assess its capacity to detect undiagnosed cancers. The
test will also allow the establishment of the rate at
which the test generates false positive results. Some
inflammatory conditions can cause elevated levels of
the same proteins picked up by the blood tests. This
could lead to cancer free individuals to be diagnosed.
The test will also need to increase its level of
sensitivity to the genes and proteins detected. Early
stage tumours release less of the detected proteins
than later stage tumours. Without an adequate level of
sensitivity this could allow early stage tumours to slip
under the radar.

The importance of early detection

In the UK around one in four cancers are diagnosed
through emergency admission to hospital. At the point
that symptoms are apparent the cancer is usually in its
later stages. Survival rates of late stage cancer are
significantly lower. This is due to the initial tumour
fragmenting and spreading throughout the body,
referred to as metastasis.
Metastatic cancer is described as being the stage of
cancer in which the initial tumour is no longer a solid
mass. Cancerous cells from the initial tumour site
break away, travelling through either the bloodstream
or the lymph vessels to other locations in the body. In
the bloodstream, these tumour cells have access to the
entire body. Some may settle in other areas or organs
of the body, forming new tumours.

This presents further complications to treatment.
Surgery may be an option to remove the initial tumour,
but the location of new tumours is highly variable. The
location of potential new tumours is dependent on the
location of the original tumour, though can be present
almost anywhere in the body. Due to the process by
which they move from the bloodstream, avoid immune
detection and begin replicating again, the tumour cells
may not be identical to those in the original tumour,
further complicating treatment.

In metastatic cancer chemotherapy is the standard
treatment. The survival rate for those with metastatic
cancer is often very low, though varies depending on
the initial cancer type. In metastatic breast cancer for
example, the five year survival rate for stage four
(metastatic) breast cancer is as low as 22 percent. By
comparison, stage three (pre-metastatic) breast
cancer has a survival rate of 72 percent. During the
initial stages of cancer, stage two survival rate is 90
percent. This is a clear indicator of the importance of
early stage detection.

On the other end of the spectrum for survival, stage 4
testicular cancer can show a survival rate as high as 80
percent. Breast cancer typically has a higher mortality
rate upon reaching the metastatic phase due to the
close proximity of a number of lymph nodes. This gives
cancerous cells access to the lymph system, and so a
greater capacity to spread throughout the body.
Implementation, and its
The impact this new test could have on cancer
mortality rates is dependent upon improvements to its
early stage detection, then its implementation.
The vision of one of the test’s creators, Dr Cristian
Tomasetti, is “a blood test we could use once a year” .
The blood test could potentially be used as a yearly
test for those above an age limit, so as to restrict its
use to those more at risk of developing cancer.

This is not an extreme vision. Being a simple blood test
the detection method is non-intrusive, and is not time
consuming for doctors to perform. This would provide a
simple means to assess a large portion of the

The creators are also intent on developing the test to
be as economical as possible. Current projections from
the creators place the cost of the test at around $500
USD per patient.

Currently, only at-risk groups of people receive
regular cancer check ups. This includes those with a
family history of cancer, or underlying genetic
conditions predisposing an individual to cancer.

Should the CancerSEEK test prove effective, it could
provide a cost efficient means to assess far larger
groups of people. This would, in theory, greatly improve
diagnosis rates at far earlier stages. This could see
the mortality rate of cancer fall further, as
significantly more people would be treated during the
early stages of the disease.


No comments:

Post a Comment

Copyright © 2015. Welcome to - All Rights Reserved
Proudly Designed By Obhiaba Blog